Abstract:Abstract Background The ONCO DVT study revealed the superiority of 12-month relative to 3-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) regarding the thrombotic risk. Methods In this pre-specified subgroup analysis of the ONCO DVT study, we stratified the patients into those with a standard edoxaban dose (60 mg/day; N=151) and those with a reduced edoxaban dose (30 mg/day; N=450) and evaluated the clinical outcomes for the 12-month and 3-month treatments. Results The cumulative 12-month incidence of symptomatic recurrent venous thromboembolism was lower in the 12-month than 3-month group for both the 60 mg (1.3% vs. 11.6%, P=0.02; odds ratio [OR], 0.12; 95% CI, 0.01–0.97) and 30 mg (1.1% vs. 7.6%, P=0.002; OR, 0.14; 95% CI, 0.03–0.60) edoxaban subgroups, which was consistent across the edoxaban doses without a significant interaction (P =0.90). The 12-month cumulative incidence of major bleeding was higher in the 12-month group than 3-month group for the 60 mg edoxaban subgroup (14.3% vs. 4.4%, P=0.046; OR, 3.61; 95% CI, 0.97–13.52), whereas it did not significantly differ between the two groups for the 30 mg edoxaban subgroup (8.7% vs. 8.6%, P=0.89; OR, 0.97; 95% CI, 0.49–1.91), signaling there was a potential interaction (P=0.07). Conclusions A 12-month edoxaban regimen for cancer-associated isolated distal DVT was consistently superior to a 3-month regimen, across the edoxaban doses for the thrombotic risk. However, caution was suggested for the standard dose of edoxaban due to the potential for an increased risk of bleeding with prolonged anticoagulation therapy.

What problem does this paper attempt to address?

This paper aims to explore the differences in the effects of 12 - month and 3 - month treatments with different doses of Edoxaban in patients with cancer - related isolated distal deep vein thrombosis (DVT). Specifically, the study focuses on the following points: 1. **Thrombosis risk**: Evaluate whether the 12 - month treatment regimen is more effective in reducing the risk of thrombosis recurrence than the 3 - month treatment regimen. 2. **Bleeding risk**: Analyze whether the 12 - month treatment regimen increases the bleeding risk, especially the differences between the standard dose (60 mg/day) and the reduced - dose (30 mg/day). ### Research background - **Cancer - related isolated distal DVT**: This type of thrombosis accounts for 11% of all cancer - related thromboses and has a negative impact on the prognosis of cancer patients. - **Recurrence risk**: Previous studies have shown that the recurrence rate of cancer - related isolated distal DVT is relatively high, approximately 5.65 per 100 person - years. - **Anticoagulant treatment**: Prolonged anticoagulant treatment may help reduce thrombosis recurrence, but it may also increase the bleeding risk at the same time. ### Research methods - **Trial design**: The ONCO DVT study is a multi - center, open - label, blinded - assessment randomized controlled trial, with a total of 601 patients enrolled. - **Grouping**: Patients were randomly assigned to the 12 - month or 3 - month Edoxaban treatment groups, and were further divided into two subgroups according to the initial dose: the standard - dose (60 mg/day) and the reduced - dose (30 mg/day). - **Primary endpoint**: The composite endpoint of symptomatic recurrent venous thromboembolism (VTE) and VTE - related death within 12 months. - **Secondary endpoints**: Major bleeding events and other clinically relevant bleeding events. ### Main findings - **Thrombosis recurrence**: - Standard - dose group: The thrombosis recurrence rate in the 12 - month treatment group was 1.3%, and that in the 3 - month treatment group was 11.6% (P = 0.02). - Reduced - dose group: The thrombosis recurrence rate in the 12 - month treatment group was 1.1%, and that in the 3 - month treatment group was 7.6% (P = 0.002). - Under both doses, the thrombosis recurrence risk in the 12 - month treatment group was significantly lower than that in the 3 - month treatment group (odds ratios were 0.12 and 0.14 respectively). - **Bleeding risk**: - Standard - dose group: The incidence of major bleeding events in the 12 - month treatment group was 14.3%, and that in the 3 - month treatment group was 4.4% (P = 0.046). - Reduced - dose group: The incidence of major bleeding events in the 12 - month treatment group was 8.7%, and that in the 3 - month treatment group was 8.6% (P = 0.89). - The 12 - month treatment in the standard - dose group increased the bleeding risk, while there was no significant difference in the reduced - dose group. ### Conclusions - **12 - month treatment regimen**: For patients with cancer - related isolated distal DVT, 12 - month Edoxaban treatment is superior to 3 - month treatment in reducing thrombosis recurrence, regardless of whether the standard dose or the reduced - dose is used. - **Bleeding risk**: The 12 - month treatment with the standard dose may increase the bleeding risk, so it should be carefully considered when choosing the treatment regimen. This study provides important clinical guidance for the treatment of cancer - related isolated distal DVT, especially when balancing the thrombosis recurrence and bleeding risks in choosing the dose of anticoagulant drugs.

Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study

Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial

The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study

Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study

Efficacy and safety of long-term edoxaban treatment for low body weight cancer patients with isolated distal deep vein thrombosis: a post-hoc subgroup analysis of the ONCO DVT study

Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study

Edoxaban, Rivaroxaban or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2

Evaluation of acute thrombus regression effect of edoxaban for deep vein thrombosis in patients with cancer: a single-center prospective observational study

Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)

Clinical outcomes of edoxaban treatment without parenteral anticoagulation therapy for acute venous thromboembolism: Insight from the COMMAND VTE Registry-2

The initial high-dose versus maintenance-dose anticoagulation therapy with direct oral anticoagulants for cancer-associated venous thromboembolism: from the COMMAND VTE Registry-2

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: A randomized clinical trial of biomarker targets

The Effectiveness and Safety of Rivaroxaban and Edoxaban in the Treatment of Lower Extremity Deep Vein Thrombosis

Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer

Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism

The effect of off-label use of reduced-dose direct oral anticoagulants therapy in the treatment of pulmonary embolism comparable to standard-dose therapy

Comparative Effectiveness and Safety of Apixaban and Low-Molecular Weight Heparin among Patients with Venous Thromboembolism and Active Cancer in an Extended Treatment Setting

Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).